Published in

American Society of Hematology, Blood, 18(128), p. 2199-2205, 2016

DOI: 10.1182/blood-2016-05-716977

Links

Tools

Export citation

Search in Google Scholar

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Journal article published in 2016 by Anthony R. Mato, Chaitra S. Ujjani, Alan P. Skarbnik, Alison R. Sehgal, Lauren E. Strelec, Alexandra Vandegrift, Clive S. Zent, Jakub Svoboda, Stephen J. Schuster, Chadi Nabhan, Paul M. Barr, Brian T. Hill, Nicole Lamanna, Christina Howlett, Danielle M. Fitzpatrick and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Key Points Toxicity was the most common reason for discontinuation of ibrutinib or idelalisib in treated patients with CLL. KI-intolerant patients, but less so those with CLL progression, can be successfully treated with an alternate KI.